Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

-- VELCADE third-quarter U.S. net sales increased 32% year-over-year to

$70.4 million --

-- Full-year financial guidance raised for second time in 2007 -- -- Phase III VISTA trial in newly diagnosed multiple myeloma stopped early due to positive interim analysis; sNDA filing now expected in December 2007

-- -- VELCADE listed in national compendia for use in newly diagnosed multiple

myeloma -- -- VELCADE label broadened by FDA providing further differentiation as

leading multiple myeloma therapy --

CAMBRIDGE, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced its financial and operational results for the third quarter of 2007. The Company raised its full-year 2007 financial guidance for the second time this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"Millennium delivered outstanding results for the quarter. U.S. net sales of VELCADE grew 32 percent over the same period last year as we fortified our leading position in relapsed multiple myeloma. The strength of our Phase III VISTA data clearly demonstrates that VELCADE has the potential to expand this leadership position into the front-line setting," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "We are raising our full- year 2007 financial guidance for the second time this year, validating the success of our strategic initiatives to accelerate growth."

"We continue to outperform financial expectations driven by accelera
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Traverse Biosciences announced today that ... development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... TRB-N0224 for the treatment and control of periodontal ... Traverse Biosciences has also granted Aratana an exclusive ... control of periodontal disease in companion animals, inclusive ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Achieved primarily ... produces slides that boast 10 to 100x better detail ... the capabilities of all existing light microscopy methods, it ... micrographs were chosen as the frame of reference because ... , The goal from the earliest discovery days ...
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... NY Researchers from the U.S. Department of Energy,s ... developed a new instrument that allows them to control ... 100 atoms with atomic precision. They created a ... developing the next generation of materials to be used ...
... Allscripts, the leading,provider of clinical software, ... improve healthcare, and the founding member of ... its firm support for the United States ... for physicians to adopt,electronic prescribing, or "e-prescribing," ...
... - Appeal of Compensatory Award Will Now Proceed -, ... today that its motion for judgment as a matter of ... of Donna Scroggin v.,Wyeth, in the U.S. District Court, Eastern ... vacates the punitive damages award of,$19,360,000 rendered by the Little ...
Cached Biology Technology:Controlling the size of nanoclusters: First step in making new catalysts 2National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 2National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 3National ePrescribing Patient Safety Initiative Supports Senate's Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety 4Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... of Adelaide are a promising step forward in helping ... babies, by reducing the likelihood of adverse inflammatory responses to ... medical procedures experienced by preterm babies, who are often anemic ... Adelaide,s Robinson Institute studied 28 preterm babies (at ...
... is a serious complication of pregnancy and the major cause ... the U.S. It affects about one in 20 pregnancies. The ... urine. The cause of preeclampsia is still unclear. Dr. Florian ... Delbrck Center (MDC) and the Charit), Dr. Ralf Dechend (ECRC ...
... causes of dementia. In Germany and Switzerland alone, around ... doubling of the number of patients worldwide within the ... including amyloid- (Aβ) among others, in patients, brains plays ... from the Department of Neuropathology at Charit and his ...
Cached Biology News:Better blood transfusions for preterm babies 2New risk factor identified for high blood pressure during pregnancy 2New risk factor identified for high blood pressure during pregnancy 3New risk factor identified for high blood pressure during pregnancy 4Alzheimer's disease in mice alleviated promising therapeutic approach for humans 2
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
... [RET-P1] to Rhodopsin Rhodopsin is a ... mammals, birds, amphibians, and reptiles. The rhodopsin ... in the retina. Immunogen: ... Specificity: This antibody specifically labels ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
Biology Products: